Phase 1 Asthma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older (any gender)
- You have been diagnosed with mild to moderate asthma for at least 12 months
- Your lung function (measured by a breathing test) is at or above 70% of the expected normal level before using an inhaler
- Your airways show a meaningful improvement of at least 12% and 200mL in breathing capacity after using an inhaler
- If you are able to have children (male or female), you must agree to use contraception during the study and for 150 days after treatment ends
- You are willing and able to follow all study rules and attend all required visits
Who may not be able to join:
- You are currently pregnant or breastfeeding
- You have a lung or breathing condition other than asthma
- You have a condition (other than asthma) that causes high levels of a certain type of white blood cell called eosinophils in your body (confirm with trial site)
- You have been hospitalised or needed steroid tablets/pills for your asthma in the past 6 months
- You have ever needed a breathing machine (ventilator) to help you breathe due to asthma
- You currently have nasal polyps (small growths inside the nose)
- Your asthma is currently severe or poorly controlled
- You have smoked or vaped in the past 12 months
- You have tuberculosis, hepatitis B, hepatitis C, or HIV
- You have received certain immune-modifying treatments (biologics) in the past 3 months (confirm with trial site)
- You have previously received specific treatments called TSLP or KIT inhibitors, such as tezepelumab or briquilimab (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 844-723-9363
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.